CLINICAL TRIALS PROFILE FOR EFFIENT
✉ Email this page to a colleague
All Clinical Trials for EFFIENT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00059215 ↗ | A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI) | Completed | Eli Lilly and Company | Phase 2 | 2003-04-01 | The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a catheter (a long thin tube) that has a small balloon on the end. In many cases, patients who have this procedure receive a stent, a small wire spring that helps keep the vessel open. |
| NCT00097591 ↗ | A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention | Completed | Daiichi Sankyo Inc. | Phase 3 | 2004-11-01 | The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke. |
| NCT00097591 ↗ | A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention | Completed | Daiichi Sankyo, Inc. | Phase 3 | 2004-11-01 | The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke. |
| NCT00097591 ↗ | A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention | Completed | Eli Lilly and Company | Phase 3 | 2004-11-01 | The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke. |
| NCT00356135 ↗ | Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event | Completed | Daiichi Sankyo Inc. | Phase 2 | 2006-07-01 | This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking clopidogrel 75 mg daily following a percutaneous coronary intervention (PCI) with placement of a stent, performed to treat acute coronary syndrome (ACS). |
| NCT00356135 ↗ | Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event | Completed | Daiichi Sankyo, Inc. | Phase 2 | 2006-07-01 | This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking clopidogrel 75 mg daily following a percutaneous coronary intervention (PCI) with placement of a stent, performed to treat acute coronary syndrome (ACS). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EFFIENT
Condition Name
Clinical Trial Locations for EFFIENT
Trials by Country
Clinical Trial Progress for EFFIENT
Clinical Trial Phase
Clinical Trial Sponsors for EFFIENT
Sponsor Name
